The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine.
about
Novel approaches to develop Rift Valley fever vaccinesCharacterization of Rift Valley fever virus MP-12 strain encoding NSs of Punta Toro virus or sandfly fever Sicilian virusCountermeasure development for Rift Valley fever: deletion, modification or targeting of major virulence factor NSsDevelopment of a novel, single-cycle replicable rift valley Fever vaccine.MP-12 virus containing the clone 13 deletion in the NSs gene prevents lethal disease when administered after Rift Valley fever virus infection in hamstersSingle-cycle replicable Rift Valley fever virus mutants as safe vaccine candidatesModifying the NSs gene to improve live-attenuated vaccine for Rift Valley fever.Rift Valley fever virus NSs inhibits host transcription independently of the degradation of dsRNA-dependent protein kinase PKR.Novel vaccine strategies against emerging viruses.Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge.Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains neuroinvasiveness in mice.Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR.The two faces of Rift Valley fever virus virulence factor NSs: The development of a vaccine and the elucidation of pathogenesis.Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain.Genetic stability of Rift Valley fever virus MP-12 vaccine during serial passages in culture cells.Bunyaviruses: from transmission by arthropods to virus entry into the mammalian host first-target cells
P2860
Q27027003-11296D6C-F446-4852-862C-9C54F6643A92Q28486276-18A49ABD-83DC-44A7-8139-F3F40A77C92EQ33705717-63639568-45A3-4258-B20D-6160DE48B34CQ35126733-5E0DE517-B45B-4966-A1A4-C155F6C2EEA1Q35792819-FF899107-580B-49E1-B908-D6616544E29AQ36326847-217921A2-4ED5-428B-9854-BF01BD8C51D0Q36489477-011B26CC-6A42-4CC6-84A8-47F93866AEFEQ36501737-25892CE3-39B9-4AA8-90BE-CDC11BDD4953Q36816140-C7FA2651-45AA-4EFE-9E1F-7CA1FAB3C445Q36879979-3EA112A0-E1A6-4F29-A656-C8E3C14D09C2Q37006803-DC57C2BE-8E60-41E7-96B2-229E227180E0Q37509225-ADCA82A9-9B55-45EA-8BDF-025BEAF5F52DQ37509231-9E778664-4572-46D3-BB0E-21F0E16D348AQ39251803-DB362397-E61C-4013-9CBE-5F2C94904730Q43167996-A9C987D4-0662-4C5A-8925-3160E5B15CDFQ44170263-DC933955-8558-4A96-9755-7134EA21B36AQ56881173-9819807E-BE57-4F11-AA82-B280B88B94F6
P2860
The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The dominant-negative inhibiti ...... ley fever virus MP-12 vaccine.
@ast
The dominant-negative inhibiti ...... ley fever virus MP-12 vaccine.
@en
type
label
The dominant-negative inhibiti ...... ley fever virus MP-12 vaccine.
@ast
The dominant-negative inhibiti ...... ley fever virus MP-12 vaccine.
@en
prefLabel
The dominant-negative inhibiti ...... ley fever virus MP-12 vaccine.
@ast
The dominant-negative inhibiti ...... ley fever virus MP-12 vaccine.
@en
P2093
P2860
P356
P1433
P1476
The dominant-negative inhibiti ...... ley fever virus MP-12 vaccine.
@en
P2093
Alexander N Freiberg
Birte Kalveram
Chien-Te K Tseng
Nandadeva Lokugamage
Olga Lihoradova
Sabarish V Indran
Terence E Hill
Terry L Juelich
Tetsuro Ikegami
P2860
P304
P356
10.1128/JVI.00778-12
P407
P577
2012-05-09T00:00:00Z